bioMérieux Stock Rebounds by 3.5% and Moves Above Its MM50
bioMérieux stock sees a significant uptick in late afternoon trading, buoyed by a general rebound in the CAC 40 after several turbulent sessions. The Lyon-based company's stock is recovering after a heavily degraded quarter, although it remains significantly down over the year. Bank of America also adjusted its rating earlier in the week.
A Rebound That Takes the Stock Above Its Short-Term Moving Averages
bioMérieux stock gains 3.33% to €71.45, as it had lost ground the previous day and tested its MM20. The stock is among the top gainers in the SBF 120, with the index up by 0.61%. This session allows the stock price to move above its MM20 (€68.87) and MM50 (€70.79), with respective increases of +3.75% and +0.93%.
The 200-day moving average (€94.32) remains significantly distant, more than 24% above the current price, highlighting the extent of the underlying decline. Over one year, the stock is still down nearly 40% and shows a -22.88% over three months. The RSI at 48 indicates momentum has returned to a neutral zone after several weeks of selling pressure, while the resistance at €74.35 remains the next visible threshold on the chart.
BofA Securities Lowers Price Target to €80 Early in the Week
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Alongside today's rebound, BofA Securities reduced its price target from €85 to €80 on July 7, while maintaining a 'hold' rating. The new target suggests a potential upside of about 12% from the current price. This adjustment follows the previous session, where the stock suffered from a deteriorated market environment.
The macroeconomic context continues to be marked by renewed tensions in the Middle East and a surge in Brent crude above $78, two factors that do not directly affect medical diagnostics but weigh on risk appetite in Europe. The next technical level to watch remains the resistance at €74.35, whose breach would condition the continuation of the rebound.
SectorSanté · Vaccins et laboratoires de recherche›Équipements Médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2025
Guidance from the release
Dans un contexte de faible activité épidémiologique, nous continuons à faire croître notre base installée, en particulier pour BIOFIRE® et SPOTFIRE®, et à améliorer la rentabilité dans le cadre du plan GO•28.
Ventes consolidées de 2 992 millions d'euros sur 9 mois (+4,2 % publié, +7,3 % organique). Forte croissance des panels non-respiratoires et de SPOTFIRE (croissance organique 114 %), ralentissement en Chine et moindre épidémiologie respiratoire. Révision de la guidance organique 2025 à +5,5 % / +6,5 %; ROCC attendu +12 % / +18 %. Effet de change négatif -85 millions d'euros sur les ventes 9 mois et ~-30 millions d'euros attendu sur le CEBIT annuel.
Risks mentioned
faible activité épidémiologique impactant les ventes de panels respiratoires
recul significatif des ventes en Chine
risque de change défavorable (impact -85 millions d'euros sur 9 mois, ~-30 millions d'euros sur CEBIT attendu)
risques liés aux économies en hyperinflation (Argentine, Turquie)
Opportunities identified
forte dynamique de SPOTFIRE (base installée >5 500, +160 % sur 12 mois)
croissance des panels non-respiratoires BIOFIRE
développements de nouveaux produits (GENE-UP® PRO HRM) et lancements soutenant les applications industrielles
croissance robuste des Applications Industrielles, notamment Contrôle Qualité Pharmaceutique (+15 %)
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
